Assembly Biosciences advances liver disease and herpesvirus programs, secures $75M from Gilead, cash runway into 2029

Assembly Biosciences initiated a Phase 2 study for ABI-6250 targeting chronic hepatitis delta virus and exercised a 40% U.S. profit-share option for the HSV helicase primase inhibitor program with Gilead. The company received a $75 million collaboration extension fee from Gilead, extending its cash runway into 2029. Research and development expenses increased due to new clinical studies, while revenue from Gilead collaboration decreased compared to last year. Upcoming milestones include Phase 2 studies for ABI-6250 in cholestatic liver diseases and GS-1179 for recurrent genital herpes.

As of Nov 13, 2026 04:11 WIB, Gilead Sciences, Inc. (GILD) shares are priced at USD 168.01 on Pluang, showing a 1-day decline of 1.01%. The stock has a market capitalization of $210.52 billion and an enterprise value of $230.32 billion. Despite the recent collaboration extension fee news, Pluang order activity heavily favors selling at 99%.